.Long-term (Investment) Activity Analysis
Difficulty: Beginner
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Ratios (Summary)
Eli Lilly & Co., long-term (investment) activity ratios
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| | Net fixed asset turnover | |||||
| | Total asset turnover | |||||
| | Equity turnover |
Source: Based on data from Eli Lilly & Co. Annual Reports
| Ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Eli Lilly & Co.'s net fixed asset turnover improved from 2015 to 2016 and from 2016 to 2017. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Eli Lilly & Co.'s total asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders' equity. | Eli Lilly & Co.'s equity turnover improved from 2015 to 2016 and from 2016 to 2017. |
Net Fixed Asset Turnover
Eli Lilly & Co., net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in thousands) | ||||||
| | Revenue | |||||
| | Property and equipment, net | |||||
| Ratio | ||||||
| | Net fixed asset turnover1 | |||||
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors | ||||||
| Abbott Laboratories | ||||||
| AbbVie Inc. | ||||||
| Allergan PLC | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Celgene Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Net Fixed Asset Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | ||||||
Source: Based on data from Eli Lilly & Co. Annual Reports
2017 Calculations
1 Net fixed asset turnover = Revenue ÷ Property and equipment, net
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Eli Lilly & Co.'s net fixed asset turnover improved from 2015 to 2016 and from 2016 to 2017. |
Total Asset Turnover
Eli Lilly & Co., total asset turnover calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in thousands) | ||||||
| | Revenue | |||||
| | Total assets | |||||
| Ratio | ||||||
| | Total asset turnover1 | |||||
| Benchmarks | ||||||
| Total Asset Turnover, Competitors | ||||||
| Abbott Laboratories | ||||||
| AbbVie Inc. | ||||||
| Allergan PLC | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Celgene Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Total Asset Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| Total Asset Turnover, Industry | ||||||
| Health Care | ||||||
Source: Based on data from Eli Lilly & Co. Annual Reports
2017 Calculations
1 Total asset turnover = Revenue ÷ Total assets
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Eli Lilly & Co.'s total asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017. |
Equity Turnover
Eli Lilly & Co., equity turnover calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in thousands) | ||||||
| | Revenue | |||||
| | Total Eli Lilly and Company shareholders' equity | |||||
| Ratio | ||||||
| | Equity turnover1 | |||||
| Benchmarks | ||||||
| Equity Turnover, Competitors | ||||||
| Abbott Laboratories | ||||||
| AbbVie Inc. | ||||||
| Allergan PLC | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Celgene Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Equity Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| Equity Turnover, Industry | ||||||
| Health Care | ||||||
Source: Based on data from Eli Lilly & Co. Annual Reports
2017 Calculations
1 Equity turnover = Revenue ÷ Total Eli Lilly and Company shareholders' equity
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders' equity. | Eli Lilly & Co.'s equity turnover improved from 2015 to 2016 and from 2016 to 2017. |
